» Articles » PMID: 35418152

The Intriguing Roles of Siglec Family Members in the Tumor Microenvironment

Overview
Journal Biomark Res
Publisher Biomed Central
Date 2022 Apr 14
PMID 35418152
Authors
Affiliations
Soon will be listed here.
Abstract

Sialic acid-binding receptors are expressed on the surfaces of a variety of immune cells and have complex and diverse immunoregulatory functions in health and diseases. Recent studies have shown that Siglecs could play diverse immune and nonimmune regulatory roles in the tumor microenvironment (TME) and participate in tumor progression through various mechanisms, such as regulating tumor growth and metastasis, mediating the inflammatory response, and promoting tumor immune escape, thereby affecting the prognoses and outcomes of patients. However, depending on the cell type in which they are expressed, each Siglec member binds to corresponding ligands in the microenvironment milieu to drive diverse cell physiological and pathological processes in tumors. Therefore, we herein summarize the expression spectra and functions of the Siglec family in human diseases, particularly cancer, and highlight the possibility of therapeutic interventions targeting the TME in the future.

Citing Articles

Immune Cell Interactions and Immune Checkpoints in the Tumor Microenvironment of Gastric Cancer.

Cozac-Szoke A, Cozac D, Negovan A, Tinca A, Vilaia A, Cocuz I Int J Mol Sci. 2025; 26(3).

PMID: 39940924 PMC: 11818890. DOI: 10.3390/ijms26031156.


Unveiling sialoglycans' immune mastery in pregnancy and their intersection with tumor biology.

Huang J, Feng L, Huang J, Zhang G, Liao S Front Immunol. 2025; 15:1479181.

PMID: 39759524 PMC: 11695303. DOI: 10.3389/fimmu.2024.1479181.


When a negative (charge) is not a positive: sialylation and its role in cancer mechanics and progression.

Habeeb I, Alao T, Delgado D, Buffone Jr A Front Oncol. 2024; 14:1487306.

PMID: 39628991 PMC: 11611868. DOI: 10.3389/fonc.2024.1487306.


Glioma-Associated Sialoglycans Drive the Immune Suppressive Phenotype and Function of Myeloid Cells.

Cornelissen L, Santegoets K, Kers-Rebel E, Bossmann S, Laan M, Granado D Pharmaceutics. 2024; 16(7).

PMID: 39065651 PMC: 11279593. DOI: 10.3390/pharmaceutics16070953.


From mechanism to therapy: the journey of CD24 in cancer.

Zhao K, Wu C, Li X, Niu M, Wu D, Cui X Front Immunol. 2024; 15:1401528.

PMID: 38881902 PMC: 11176514. DOI: 10.3389/fimmu.2024.1401528.


References
1.
Angata T . Siglec-15: a potential regulator of osteoporosis, cancer, and infectious diseases. J Biomed Sci. 2020; 27(1):10. PMC: 6941304. DOI: 10.1186/s12929-019-0610-1. View

2.
Chavez-Galan L, Olleros M, Vesin D, Garcia I . Much More than M1 and M2 Macrophages, There are also CD169(+) and TCR(+) Macrophages. Front Immunol. 2015; 6:263. PMC: 4443739. DOI: 10.3389/fimmu.2015.00263. View

3.
Liao J, Zeng D, Li J, Hua Q, Huang C, Xu J . Type I IFNs repolarized a CD169 macrophage population with anti-tumor potentials in hepatocellular carcinoma. Mol Ther. 2021; 30(2):632-643. PMC: 8821951. DOI: 10.1016/j.ymthe.2021.09.021. View

4.
Chang J, Peng H, Shaffer B, Baskar S, Wecken I, Cyr M . Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies. Cancer Immunol Res. 2018; 6(9):1008-1013. PMC: 6125214. DOI: 10.1158/2326-6066.CIR-18-0102. View

5.
Meril S, Harush O, Reboh Y, Matikhina T, Barliya T, Cohen C . Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells. Mol Carcinog. 2020; 59(7):713-723. DOI: 10.1002/mc.23213. View